Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382980 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 308
- Enrollment target
NCT00382980: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00382980 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 308 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (413% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00382980, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 308 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare how the body reacts to different strengths of an experimental cell culture-grown whole virus A/H5N1 flu vaccine when given with or without the addition of aluminum hydroxide adjuvant. Researchers will also look at how much antibody is made to the influenza virus hemagglutinin (HA) after subjects receive the H5N1 vaccine. Three hundred healthy adults aged 18-40 years will participate for approximately 9 months, which includes screening. Participants will receive 2 doses of vaccine or placebo injected 28 days apart. Participants will have blood samples taken up to 7 times and have 8 scheduled study visits.
Interventions
- DRUG Placebo
- BIOLOGICAL Aluminum hydroxide
- BIOLOGICAL Inactivated Vero cell based whole virus influenza A/H5N1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
What the finished NCT00382980 record still lists
NCT00382980 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (413% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00382980 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00382980 about?
NCT00382980 is a clinical study titled "Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults". The purpose of this research study is to compare how the body reacts to different strengths of an experimental cell culture-grown whole virus A/H5N1 flu vaccine when given with or without the addition of aluminum hydroxide adjuvant. Researchers will also look at how much antibody is made to the infl...
What is the current status of trial NCT00382980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 308 participants. The study started on 2006-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00382980?
The interventions under investigation include: Placebo (DRUG), Aluminum hydroxide (BIOLOGICAL), Inactivated Vero cell based whole virus influenza A/H5N1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00382980?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00382980's enrollment target sits among peer trials
308 122nd of 2000 higher than 1,877 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia